A patient with high-risk POD24 follicular lymphoma achieved durable complete remission after treatment with Carteuva CD19 CAR-T therapy. This case highlights the growing role of CAR-T therapy in patients with early relapse and limited treatment options.
Five-year follow-up data from Yescarta (axi-cel) continues to demonstrate durable survival and long-term remission in patients with relapsed or refractory large B-cell lymphoma, supporting its role as a potential curative treatment and establishing a new standard of care in China.
CAR-T cell therapy for large B-cell lymphoma offers a breakthrough option for relapsed or refractory cases, using engineered immune cells to target CD19-positive cancer cells with high remission rates.
CAR-T cell therapy has transformed the treatment landscape for relapsed and refractory mantle cell lymphoma. Learn how this innovative immunotherapy works, who may benefit, and what patients can expect when seeking treatment in China.
A new real-world multicenter study in patients with relapsed or refractory large B-cell lymphoma shows that second-line CAR-T cell therapy is associated with a lower hematologic toxicity burden, improved safety profile, and favorable survival outcomes compared with later-line treatment settings.
A new modeling study reveals that lowering tumor burden before CAR-T infusion could significantly improve outcomes in lymphoma, offering a new strategy to enhance long-term remission.
New Phase II data from China demonstrate that relma-cel CAR-T therapy delivers high response rates and durable survival in heavily pretreated relapsed/refractory mantle cell lymphoma patients.
At ASH 2025, researchers from Shenzhen University General Hospital reported updated Phase I/II data showing CD19/CD20 dual-target CAR-T therapy achieved a 77% ORR and durable responses with controllable safety in relapsed/refractory B-cell lymphoma.
A Phase I study from Beijing reports highly promising results for CD7 CAR-T therapy in relapsed or refractory T-cell lymphoma, achieving a 92.5% response rate and 77.5% complete remission. The treatment showed encouraging survival outcomes, especially in patients who proceeded to allo-HSCT consolidation.
China approves a second indication for the homegrown CD19 CAR-T therapy Yorwida, bringing new hope to patients with relapsed or refractory large B-cell lymphoma.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.